Erratum: Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: Results fromthe REDECT trial (Journal of Clinical Oncology (2013) 31 (187-194) DOI: 10.1200/JCO.2011.41.2445);Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: Results from the REDECT trial

Journal of Clinical Oncology

Volumn 31, Issue 2, 2013, Pages 187-194

  Divgi, Chaitanya R ^a   Uzzo, Robert G ^c   Gatsonis, Constantine ^d   Bartz, Roman ^e   Treutner, Silke ^e   Yu, Jian Qin ^c   Chen, David ^c   Carrasquillo, Jorge A ^b   Larson, Steven ^b   Bevan, Paul ^e   Russo, Paul ^b  

^a NewYork Presbyterian Hospital   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d BROWN UNIVERSITY   (United States)

^e Wilex Biotechnology GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GIRENTUXIMAB I 124;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIARRHEA; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE;

EID: 84872511470     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.76.9950     Document Type: Erratum

References (48)

1. Siegel R, Ward E, Brawley O, et al: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236, 2011
2. Linehan WM, Walther MM, Zbar B: The genetic basis of cancer of the kidney. J Urol 170:2163-2172, 2003 (Pubitemid 37413950)
3. Gill IS, Aron M, Gervais DA, et al: Small renal mass. N Engl J Med 362:624-634, 2010
4. Klatte T, Pantuck AJ, Kleid MD, et al: Understanding the natural biology of kidney cancer: Implications for targeted cancer therapy. Rev Urol 9:47-56, 2007
5. Kattan MW, Reuter V, Motzer RJ, et al: A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166:63-67, 2001 (Pubitemid 32565343)
6. Sorbellini M, Kattan MW, Snyder ME, et al: A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173:48-51, 2005 (Pubitemid 39627669)
7. Motzer RJ, Bacik J, Mariani T, et al: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20:2376-2381, 2002 (Pubitemid 34441667)
8. Cheville JC, Lohse CM, Zincke H, et al: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27:612-624, 2003 (Pubitemid 36514472)
9. Gudbjartsson T, Hardarson S, Petursdottir V, et al: Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: A retrospective nation-wide study of 629 patients. Eur Urol 48:593-600, 2005 (Pubitemid 41278584)
10. Leibovich BC, Lohse CM, Crispen PL, et al: Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 183:1309-1315, 2010
11. Berland LL, Silverman SG, Gore RM, et al: Managing incidental findings on abdominal CT: White paper of the ACR incidental findings committee. J Am Coll Radiol 7:754-773, 2010
12. Huang WC, Levey AS, Serio AM, et al: Chronic kidney disease after nephrectomy in patients with renal cortical tumours: A retrospective cohort study. Lancet Oncol 7:735-740, 2006 (Pubitemid 44283660)
13. Huang WC, Elkin EB, Levey AS, et al: Partial nephrectomy versus radical nephrectomy in patients with small renal tumors: Is there a difference in mortality and cardiovascular outcomes? J Urol 181:55-61, 2009; discussion 61-62
14. Zini L, Perrotte P, Capitanio U, et al: Radical versus partial nephrectomy: Effect on overall and noncancer mortality. Cancer 115:1465-1471, 2009
15. Novick AC, Campbell SC, Belldegrun A, et al: Guideline for Management of the Clinical Stage 1 Renal Mass. American Urological Association Education and Research, 2009. http://www.auanet.org/content/ guidelines-and-quality-care/ clinical-guidelines/mainreports/ renalmass09.pdf
16. Leveridge MJ, Finelli A, Kachura JR, et al: Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol 60:578-584, 2011
17. Larson S, Sarnes M, McLaughlin T, et al: Real world use of diagnostic procedures in renal cell carcinoma. J Nucl Med 52, 2011 (suppl 1; abstr 1419)
18. Volpe A, Mattar K, Finelli A, et al: Contemporary results of percutaneous biopsy of 100 small renal masses: A single center experience. J Urol 180:2333-2337, 2008
19. Belov VV, Bonab AA, Fischman AJ, et al: Iodine-124 as a label for pharmacological PET imaging. Mol Pharm 8:736-747, 2011
20. Stillebroer AB, Mulders PF, Boerman OC, et al: Carbonic anhydrase IX in renal cell carcinoma: Implications for prognosis, diagnosis, and therapy. Eur Urol 58:75-83, 2010
21. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al: Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial. Lancet Oncol 8:304-310, 2007 (Pubitemid 46464522)
22. Kim JK, Kim TK, Ahn HJ, et al: Differentiation of subtypes of renal cell carcinoma on helical CT scans. AJR Am J Roentgenol 178:1499-1506, 2002 (Pubitemid 34547840)
23. Eble JN, Sauter G, Epstein JI, et al (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France, IARC Press, 2004
24. Obuchowski N, Rockette HE: Hypothesis testing of diagnostic accuracy for multiple readers and multiple tests: An ANOVA approach with dependent observations. Commun Stat Simul Comput 24:285-308, 1995
25. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 33:159-174, 1977 (Pubitemid 8054849)
26. Kutikov A, Fossett LK, Ramchandani P, et al: Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology 68:737-740, 2006 (Pubitemid 44633357)
27. Schachter LR, Cookson MS, Chang SS, et al: Second prize: Frequency of benign renal cortical tumors and histologic subtypes based on size in a contemporary series: What to tell our patients. J Endourol 21:819-823, 2007 (Pubitemid 47443652)
28. Snyder ME, Bach A, Kattan MW, et al: Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: Influence of sex. J Urol 176:2391-2395, 2006; discussion 2395-2396
29. Frank I, Blute ML, Cheville JC, et al: Solid renal tumors: An analysis of pathological features related to tumor size. J Urol 170:2217-2220, 2003 (Pubitemid 37413960)
30. Maturen KE, Nghiem HV, Caoili EM, et al: Renal mass core biopsy: Accuracy and impact on clinical management. AJR Am J Roentgenol 188: 563-570, 2007 (Pubitemid 46167760)
31. Neuzillet Y, Lechevallier E, Andre M, et al: Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses. J Urol 171:1802-1805, 2004 (Pubitemid 38501006)
32. Wood BJ, Khan MA, McGovern F, et al: Imaging guided biopsy of renal masses: Indications, accuracy and impact on clinical management. J Urol 161:1470-1474, 1999 (Pubitemid 29420798)
33. Samplaski MK, Zhou M, Lane BR, et al: Renal mass sampling: An enlightened perspective. Int J Urol 18:5-19, 2011
34. Lane BR, Samplaski MK, Herts BR, et al: Renal mass biopsy: A renaissance? J Urol 179:20-27, 2008
35. Herts BR, Baker ME: The current role of percutaneous biopsy in the evaluation of renal masses. Semin Urol Oncol 13:254-261, 1995
36. Wang R, Wolf JS Jr, Wood DP Jr, et al: Accuracy of percutaneous core biopsy in management of small renal masses. Urology 73:586-590, 2009; discussion 590-591
37. Volpe A, Kachura JR, Geddie WR, et al: Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol 178:379-386, 2007 (Pubitemid 47030509)
38. Smaldone MC, Kutikov A, Egleston BL, et al: Small renal masses progressing to metastases under active surveillance: A systematic review and pooled analysis. Cancer 118:997-1006, 2012
39. Jewett MA, Mattar K, Basiuk J, et al: Active surveillance of small renal masses: Progression patterns of early stage kidney cancer. Eur Urol 60:39-44, 2011
40. Bahnson EE, Murrey DA, Mojzisik CM, et al: PET/CT imaging of clear cell renal cell carcinoma with I labeled chimeric antibody. Ther Adv Urol 1:67-70, 2009
41. Povoski SP, Hall NC, Murrey DA Jr, et al: Multimodal imaging and detection strategy with 124 I-labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparascopic and open surgical resection of clear cell renal cell carcinoma. Surg Innov [epub ahead of print on April 11, 2012]
42. Juweid ME, Wiseman GA, Vose JM, et al: Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23:4652-4661, 2005 (Pubitemid 46224067)
43. Weber WA: Assessing tumor response to therapy. J Nucl Med 50:1S-10S, 2009 (suppl 1)
44. Krajewski KM, Giardino AA, Zukotynski K, et al: Imaging in renal cell carcinoma. Hematol Oncol Clin North Am 25:687-715, 2011
45. Frangioni JV: The problem is background, not signal. Mol Imaging 8:303-304, 2009
46. Kwekkeboom DJ, Kam BL, van Essen M, et al: Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 17:R53-R73, 2010
47. Dehdashti F, Mortimer JE, Trinkaus K, et al: PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 113:509-517, 2009
48. U.S. Food and Drug Administration: FDA's Critical Path Initiative; January 20, 2011. http://www.fda.gov/ScienceResearch/SpecialTopics/ CriticalPathInitiative/ucm076689.htm